Characterized by the World Health Organization as a “neglected tropical disease,” leprosy (also known as Hansen’s disease) is caused by Mycobacterium leprae. Nearly a quarter of a million people are diagnosed with [Read more]
Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The first reported [Read more]
The Experimental Therapeutics (ET) Branch of the Walter Reed Army Institute of Research (WRAIR) focuses on the development of new drugs to prevent and treat malaria, leishmaniosis, antibiotic-resistant bacteria, and other infectious [Read more]
Humanetics Corporation has been awarded a three-year contract valued at approximately $5.4 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The contract [Read more]
AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale [Read more]
The Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation and Ventures (DRIVe) is seeking applicants interested in working with BARDA DRIVe as part of a network of accelerators across [Read more]
The U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) will purchase an anthrax treatment for $25.2 million from Elusys Therapeutics Inc. of [Read more]
The Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) is conducting market research on all qualified vendors of business intelligence software for influenza vaccine supply chain [Read more]
The U.S. Centers for Disease Control and Prevention is seeking a vendor who can obtain anonymous pre- and post-immunization sera from specified age-groups of Europeans. The study must be conducted in a [Read more]
AbCellera Biologics Inc. this week announced that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop rapid countermeasures against viral outbreaks. Under DARPA’s Pandemic Prevention Platform (P3) [Read more]
© 2018 Global Biodefense